ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: juvenile idiopathic arthritis

Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium

  |  

Therapy with tumor necrosis factor inhibitors, nonsteroidal antiinflammatory drugs, ustekinumab in early stages of osteitis may halt molecular switching to bone-forming phenotype characteristic of SpA

Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

Kathleen Louden  |  

Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.

JIA: The Transition to Adult Care

  |  

Experts addressed considerations for how to aid patients with juvenile idiopathic arthritis (JIA) in their transition to adult care, specifically highlighting clinical pearls for those with pediatric uveitis and TMJ arthritis.

Benefits of Early Initiation of Biologic DMARDs in pJIA

  |  

The early initiation of biologic disease-modifying anti-rheumatic drugs (DMARDs) may reduce the overall disease burden in patients with polyarticular juvenile idiopathic arthritis (pJIA), according to findings from Ringold et al.

Trends in the Use of DMARDs for Patients with JIA

  |  

Yalamanchili et al. describe how trends in disease-modifying anti-rheumatic drug (DMARD) use have evolved for insured, U.S. patients with juvenile idiopathic arthritis. Overall, the study found that from 2000 to 2022 in this patient population the use of biologic and targeted synthetic DMARDs rose, while the use of conventional synthetic DMARDs declined.